登录 | 注册    关注公众号  
微信公众号
搜索
 > 【MIS RII】

MIS RII信息

英文名称:Anti-Mullerian hormone receptor II
中文名称:抗苗勒氏管激素受体II
靶点别称:Anti-Mullerian Hormone Receptor, Type II,AMHR2,MRII,AMH Type II Receptor,MISRII,Muellerian Inhibiting Substance Type II Receptor,MIS Type II Receptor,Anti-Muellerian hormone type-2 receptor,EC:2.7.11.30,Mullerian Inhibiting Substance Type II Receptor,MISR2,AMHR,Anti-Muellerian Hormone Type-2 Receptor,Anti-Mullerian Hormone Receptor Type 2,EC 2.7.11.30,Anti-Muellerian Hormone Type II Receptor,Anti-Mullerian Hormone Receptor Type II
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

MIS RII产品列表

ACRO质量管理体系
 
评论(1)
MII-H52H6|Human MIS RII Protein, His Tag
  1. 158XXXXXXX8
  2. 0人赞
  3. 购买human种属的MIS RII蛋白,his标签,用于抗体的Elisa筛选实验,蛋白质量可靠,纯度高,活性好,满足实验要求。
  4. 2024-01-24
 

MIS RII分子别名

MIS RII,MRII,AMHR2,AMHR,MISR2,AMH type II receptor

MIS RII分子背景

MIS RII (Mullerian inhibiting substance type II receptor), also known as AMHRII (anti-Mullerian hormone type II receptor), is a serine/threonine receptor with a single transmembrane domain that belongs to the family of type II receptors of the TGF-beta superfamily. Mutations in MIS RII result in persistent Mullerian duct syndrome (PMDS), persistent Müllerian duct syndrome (PMDS) is a sex-limited disorder in which males develop portions of the female reproductive tract. Anti-Müllerian hormone (AMH) and its receptor (AMHR2) induce the regression of the Müllerian ducts in male embryos, but the mechanism by which the Amhr2 gene is specifically activated is not fully understood.

MIS RII临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Murlentamab 3C23-K; GM-102 临床二期 Lfb Biotechnologies Sas 结直肠癌, 女性生殖系统癌症 详情

消息提示

请输入您的联系方式,再点击提交!

确定